Cellectis (NASDAQ:CLLS) Stock Price Down 5.7%


Share on StockTwits

Shares of Cellectis S.A. (NASDAQ:CLLS) fell 5.7% during mid-day trading on Tuesday . The company traded as low as $18.80 and last traded at $21.94. 706,248 shares changed hands during mid-day trading, an increase of 52% from the average session volume of 465,118 shares. The stock had previously closed at $23.26.

A number of brokerages recently issued reports on CLLS. Zacks Investment Research upgraded Cellectis from a “sell” rating to a “hold” rating in a research note on Monday, February 8th. William Blair restated a “buy” rating on shares of Cellectis in a research note on Wednesday, November 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $23.40.

The company has a current ratio of 6.11, a quick ratio of 6.00 and a debt-to-equity ratio of 0.10. The company has a 50-day simple moving average of $28.25 and a 200 day simple moving average of $22.72. The firm has a market cap of $932.14 million, a PE ratio of -11.16 and a beta of 2.59.

A number of institutional investors have recently added to or reduced their stakes in CLLS. KBC Group NV boosted its position in Cellectis by 43.5% in the 3rd quarter. KBC Group NV now owns 48,082 shares of the biotechnology company’s stock worth $890,000 after purchasing an additional 14,569 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in Cellectis by 80.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 41,397 shares of the biotechnology company’s stock worth $766,000 after purchasing an additional 18,445 shares in the last quarter. ARK Investment Management LLC boosted its position in Cellectis by 48.8% in the 3rd quarter. ARK Investment Management LLC now owns 4,135,083 shares of the biotechnology company’s stock worth $76,499,000 after purchasing an additional 1,355,756 shares in the last quarter. OneAscent Financial Services LLC boosted its position in Cellectis by 25.3% in the 3rd quarter. OneAscent Financial Services LLC now owns 21,881 shares of the biotechnology company’s stock worth $405,000 after purchasing an additional 4,413 shares in the last quarter. Finally, Bpifrance SA purchased a new stake in Cellectis in the 3rd quarter worth approximately $7,876,000. Institutional investors and hedge funds own 33.30% of the company’s stock.

About Cellectis (NASDAQ:CLLS)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia.

See Also: Percentage Gainers

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.